Market Overview

UPDATE: Stifel Nicolaus Initiates Geron Corporation at Buy with $4 PT; Oncology Refocus Paying Off

Share:
Related GERN
BioTime CEO Explains What Could Happen To Stem Cell Research And The Company Under A New Guard In Washington
BioTime CEO Shares Updates On Spinal Cord Injury And Dry AMD Therapies

Stifel Nicolaus initiated coverage on Geron Corporation (NASDAQ: GERN) with a Buy rating and a price target of $4 a share.

Stifel Nicolaus noted, "We anticipate positive proof-of-concept data for Geron's two oncology assets to reignite investor interest. In our opinion, six Phase 2 data readouts over the next six to nine months should validate Imetelstat and GRN1005 as compelling, differentiated oncology clinical candidates with large commercial opportunities. We believe positive news flow will yield significant stock price appreciation for GERN."

Geron Corporation closed at $2.44 on Wednesday.

Latest Ratings for GERN

DateFirmActionFromTo
Aug 2016BTIG ResearchInitiates Coverage onNeutral
Dec 2015Janney CapitalInitiates Coverage onBuy
Apr 2015OppenheimerInitiates Coverage onOutperform

View More Analyst Ratings for GERN
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (GERN)

View Comments and Join the Discussion!